DocGo Inc.
Business
DocGo Inc. operates a vertically integrated healthcare services platform delivering mobile health services, virtual care management, and medical ambulance transportation across all 50 U.S. states and the United Kingdom. Its mobile health segment provides in-home clinical services including preventive care and chronic disease management to hospitals, health plans and employers. Its transportation segment, branded Ambulnz, operates a digitally-enabled ambulance fleet with proprietary electronic medical record integration. The company serves government entities, health systems and insurance payors through long-term contracts.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues, net | 322 | 617 | 624 | 441 | 319 | |
| Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 223 | 403 | 429 | 286 | 209 | |
| General and administrative | 133 | 139 | 137 | 103 | 75 | |
| Depreciation and amortization | 16 | 16 | 16 | 11 | 8 | |
| Legal and regulatory | 24 | 17 | 13 | 9 | 4 | |
| Technology and development | 14 | 12 | 11 | 5 | 3 | |
| Sales, advertising and marketing | 1 | 2 | 3 | 5 | 5 | |
| Intangible asset impairment | 31 | 0 | 0 | — | — | |
| Goodwill impairment | 58 | 0 | 0 | −3 | 0 | |
| Total expenses | 500 | 588 | 609 | 419 | 303 | |
| (Loss) income from operations | −178 | 29 | 15 | 22 | 15 | |
| Interest (expense) income, net | −1 | −2 | 2 | 762,685 | — | |
| (Loss) gain on change in fair value of contingent consideration | −2 | 9 | 1 | 0 | 0 | |
| Finite-lived intangible asset impairment | 0 | −8 | 0 | — | — | |
| Loss on equity method investments | −552,763 | −316,044 | −343,336 | — | — | |
| Equity investment impairment | −5 | 0 | 0 | — | — | |
| Loss on remeasurement of operating and finance leases | −42,367 | −32,363 | −866 | 1 | 0 | |
| (Loss) gain on disposal of assets | −39,668 | 23,682 | −852,544 | −21,173 | −34,342 | |
| Other (expense) income | −532,418 | 228,666 | −686,865 | −987,482 | −40,086 | |
| Total other expense (income) | −9 | −939,724 | 1 | 950,264 | −40,086 | |
| Net (loss) income before income tax expense | −187 | 28 | 16 | 23 | 20 | |
| Provision for income taxes | −9 | −14 | −6 | 8 | −615,697 | |
| Net (loss) income | −196 | 13 | 10 | 31 | 19 | |
| Net (loss) income attributable to noncontrolling interests | −14 | −7 | 3 | −4 | −5 | |
| Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries | −182 | 20 | 7 | 35 | 24 | |
| Unrealized gain on investments, net of tax | 85,635 | 0 | 0 | — | — | |
| Foreign currency translation adjustment | 1 | −263,036 | 743,699 | 773,707 | 16,038 | |
| Total comprehensive (loss) income | −181 | 20 | 8 | 35 | 24 | |
| Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Basic (in Dollars per share) | −1.84 | 0.2 | 0.07 | 0.34 | 0.3 | |
| Weighted-average shares outstanding - Basic (in Shares) | 99 | 102 | 104 | 101 | 80 | |
| Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted (in Dollars per share) | −1.84 | 0.18 | 0.06 | 0.34 | 0.25 | |
| Weighted-average shares outstanding - Diluted (in Shares) | 99 | 109 | 106 | 103 | 95 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 51 | 89 | 59 | 157 | 176 | |
| Accounts receivable, net of allowance for credit loss of $8,299,053 and $5,873,942 as of December 31, 2025 and December 31, 2024, respectively | 93 | 211 | 262 | 103 | — | |
| Prepaid expenses | 5 | 4 | — | — | 2 | |
| Other current assets | 4 | 338,665 | — | — | — | |
| Total current assets | 152 | 304 | 339 | 271 | 256 | |
| Property and equipment, net | 15 | 15 | 17 | 21 | 13 | |
| Intangibles, net | 0 | 26 | 38 | 23 | 11 | |
| Goodwill | 19 | 47 | 48 | 39 | 9 | |
| Restricted cash and cash equivalents | 1 | 18 | — | — | — | |
| Restricted investments (amortized cost of $15,737,694 and $0 as of December 31, 2025 and December 31, 2024, respectively) | 16 | 0 | — | — | — | |
| Operating lease right-of-use assets | 12 | 12 | 10 | 9 | 4 | |
| Finance lease right-of-use assets | 17 | 15 | 12 | 9 | 9 | |
| Investments | 0 | 6 | 553,573 | — | — | |
| Deferred tax assets | 538,864 | 8 | 12 | 10 | — | |
| Other assets | 3 | 4 | 3 | 4 | 4 | |
| Total assets | 217 | 456 | 490 | 393 | 310 | |
| Accounts payable | 11 | 28 | 20 | 22 | 16 | |
| Accrued liabilities | 43 | 50 | 91 | 32 | 35 | |
| Line of credit | 0 | 30 | 25 | 0 | 25,881 | |
| Notes payable, current | 51,740 | 12,515 | 28,131 | 664,913 | 600,449 | |
| Due to seller | 336,982 | 28,656 | 8 | 26 | — | |
| Contingent consideration, current | 3 | 5 | — | — | — | |
| Operating lease liability, current | 5 | 4 | 3 | 2 | 1 | |
| Finance lease liability, current | 6 | 5 | 4 | 3 | 3 | |
| Total current liabilities | 67 | 122 | 170 | 100 | 58 | |
| Notes payable, non-current | 183,843 | 5,215 | 41,586 | 1 | — | |
| Contingent consideration, non-current | 5 | 0 | — | — | — | |
| Operating lease liability, non-current | 8 | 9 | 7 | 7 | 3 | |
| Finance lease liability, non-current | 11 | 10 | 8 | 6 | 7 | |
| Total liabilities | 91 | 140 | 185 | 114 | 83 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 98,640,059 and 101,910,883 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | 9,864 | 10,191 | 10,406 | 10,241 | 10,013 | |
| Additional paid-in-capital | 325 | 321 | 321 | 301 | 283 | |
| Accumulated deficit | −184 | −1 | −21 | −29 | −64 | |
| Accumulated other comprehensive income | 2 | 1 | 1 | 741,206 | −32,501 | |
| Total stockholders equity attributable to DocGo Inc. and Subsidiaries | 144 | 321 | 301 | 273 | 220 | |
| Noncontrolling interests | −18 | −6 | 4 | 6 | 7 | |
| Total stockholders equity | 126 | 315 | 305 | 279 | 227 | |
| Total liabilities and stockholders equity | 217 | 456 | 490 | 393 | 310 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 5 | 6 | 5 | 4 | — | |
| Amortization of intangible assets | 6 | 6 | 5 | 3 | 2 | |
| Amortization of finance lease right-of-use assets | 5 | 5 | 6 | 3 | 3 | |
| Deferred income tax | 8 | 3 | −2 | −10 | 0 | |
| Accretion of discount related to restricted investments | −309,842 | 0 | 0 | — | — | |
| Loss on equity method investments | 552,763 | 316,044 | 343,336 | — | — | |
| Bad debt expense | 12 | 5 | 4 | 4 | 4 | |
| Stock-based compensation | 17 | 14 | 21 | 8 | 1 | |
| Loss on liquidation of business | 0 | 0 | 70,284 | 0 | 0 | |
| Intangible asset impairment | 31 | 8 | 0 | — | — | |
| Accounts receivable | 112 | 41 | −161 | −8 | −58 | |
| Prepaid expenses and other current assets | −3 | 13 | −11 | −4 | −961,165 | |
| Other assets | 409,156 | −1 | 1 | 2 | −2 | |
| Accounts payable | −18 | 8 | −2 | 4 | 12 | |
| Accrued liabilities | −10 | −42 | 59 | −6 | 21 | |
| Operating lease liabilities and right-of-use assets | 200,221 | 32,834 | 0 | — | — | |
| Net cash provided by (used in) operating activities | 34 | 70 | −64 | 29 | −2 | |
| Purchase of property and equipment | −5 | −4 | −7 | −3 | −5 | |
| Purchase of intangibles | −3 | −2 | −3 | −2 | −2 | |
| Acquisition of businesses, net of cash acquired | −16 | 0 | −20 | −33 | −1 | |
| Purchase of restricted investments | −29 | 0 | 0 | — | — | |
| Purchase of equity method investments | −4,784 | −310,450 | −298,932 | 0 | −655,876 | |
| Purchase of equity securities | 0 | −5 | 0 | 0 | — | |
| Proceeds from sale and maturity of restricted investments | 13 | 0 | 0 | — | — | |
| Proceeds from disposal of property and equipment | 202,167 | 274,427 | 747,088 | 3,000 | 74,740 | |
| Net cash used in investing activities | −39 | −11 | −30 | −38 | −9 | |
| Proceeds from revolving credit line | 0 | 45 | 25 | 0 | 8 | |
| Repayments of revolving credit line | −30 | −40 | 0 | −25,881 | — | |
| Proceeds from notes payable | 258,700 | 0 | 0 | — | — | |
| Repayments of notes payable | −41,247 | −51,987 | −25,926 | −925,151 | −604,826 | |
| Due to seller | −877,713 | −3 | −14 | −3 | −595,528 | |
| Acquisition of noncontrolling interest | 0 | −2 | 0 | 0 | — | |
| Earnout payments on contingent liabilities | −2 | −4 | −5 | 0 | 0 | |
| Distributions paid to noncontrolling interest | −175,831 | −1 | 0 | 0 | — | |
| Proceeds from exercise of stock options | 0 | 26,330 | 2 | 2 | 628,592 | |
| Payments for taxes related to shares withheld for employee taxes | −2 | −1 | −2 | 0 | 0 | |
| Common stock repurchased | −11 | −14 | 0 | −4 | 0 | |
| Payments on obligations under finance lease | −5 | −4 | −4 | −3 | −2 | |
| Net cash (used in) provided by financing activities | −51 | −24 | 1 | −6 | 155 | |
| Effect of exchange rate changes on cash and cash equivalents | 595,803 | −190,639 | 1 | 761,232 | −21,414 | |
| Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | −55 | 35 | −92 | −15 | 145 | |
| Cash paid for interest | 2 | 2 | 250,100 | 197,005 | 315,272 | |
| Cash paid for interest on finance lease liabilities | 958,553 | 769,041 | 600,239 | 559,596 | 525,476 | |
| Cash paid for income taxes, net of refunds | 6 | 6 | 10 | 2 | 615,697 | |
| Right-of-use assets obtained in exchange for lease liabilities | 12 | 14 | 8 | 5 | 5 | |
| Remeasurement of finance lease right-of-use asset due to lease modification | 0 | 300,000 | 0 | 0 | — | |
| Property and equipment in accounts payable | 52,866 | 221,639 | 271,292 | — | — | |
| CRMS True-up Payment through issuance of stock | 0 | 2 | 0 | 0 | — | |
| Receivables exchanged for trade credits | 0 | 0 | 2 | 0 | 0 | |
| Pre-acquisition receivables written off through due to seller | 0 | 5 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is DocGo Inc.'s CIK number?
DocGo Inc.'s SEC CIK number is 0001822359 (1822359). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find DocGo Inc.'s SEC filings?
All of DocGo Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did DocGo Inc. last report earnings?
DocGo Inc. (DCGO) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001822359-26-000020). This is DocGo Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is DocGo Inc.'s most recent earnings 8-K?
DocGo Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001822359-26-000020. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View DocGo Inc.'s latest earnings 8-K →
Look up any company's CIK number →